All In Biotech

Drug Trial Radar · NCT07276373

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Sep 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.

Conditions

  • Neoplasms

Interventions

  • Nenocorilant 200 mgDrug

    Nenocorilant 200 mg will be supplied as 50 and/or 100 mg tablets.

  • Nenocorilant 300 mgDrug

    Nenocorilant 300 mg will be supplied as 50 and/or 100 mg tablets.

  • Nenocorilant 400 mgDrug

    Nenocorilant 400 mg will be supplied as 50 and/or 100 mg tablets.

  • NivolumabDrug

    Nivolumab 240 mg and 480 mg will be supplied as single-dose 120 mg/12 mL (10 mg/mL) vials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients With 1 or More Adverse EventTime frame: From first dose of study treatment up to 28 days after final dose, assessed up to 9 months
  2. Number of Patients With 1 or More Serious Adverse EventsTime frame: From first dose of study treatment up to 28 days after final dose, assessed up to 9 months
  3. Number of Patients With 1 or More Adverse Events Leading to Study Drug DiscontinuationTime frame: From first dose of study treatment up to final dose, assessed up to 9 months
  4. Percent of Patients who Experience Dose Limiting Toxicity (DLT)Time frame: Up to 28 days after initiation of Cycle 1 (each cycle consists of 28 days)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Site 03

    Los Angeles, California · Recruiting

  • Site 05

    Chicago, Illinois · Recruiting

  • Site 04

    Grand Rapids, Michigan · Recruiting

  • Site 01

    San Antonio, Texas · Recruiting

  • Site 02

    West Valley City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.